AbCellera Biologics (ABCL) Non-Current Assets (2020 - 2026)

AbCellera Biologics has reported Non-Current Assets for 7 years, with the latest figure at $642.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 10.93% year-over-year to $642.5 million; the trailing twelve-month figure through Mar 2026 stood at $642.5 million (up 10.93% YoY), and the FY2025 full-year result was $628.7 million, up 3.21% from the prior year.
• Non-Current Assets for Q1 2026 stood at $642.5 million, up from $628.7 million in the prior quarter.
• The five-year high for Non-Current Assets was $660.9 million in Q3 2025, with the low at $417.9 million in Q1 2022.
• Historically, Non-Current Assets has averaged $587.2 million across 5 years, with a median of $609.2 million in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Assets surged 89.49% — and 2025, when it dropped 10.77%.
• AbCellera Biologics' Non-Current Assets stood at $515.4 million in 2022, then climbed by 19.54% to $616.1 million in 2023, then slipped by 1.12% to $609.2 million in 2024, then climbed by 3.21% to $628.7 million in 2025, then increased by 2.19% to $642.5 million in 2026.
• The last three Non-Current Assets figures came in at $642.5 million (Q1 2026), $628.7 million (Q4 2025), and $660.9 million (Q3 2025), per Business Quant data.